Clinical Trials | April 16, 2024
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
A five-day inspection was concluded successfully with no critical and no major observations raised
ANVISA issues CGMP to Concord Biotech’s Unit I
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
The companies will work with investigators to share the results with the scientific community
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Subscribe To Our Newsletter & Stay Updated
